UniQure’s Glybera 1st Gene Therapy Approved In EU

Law360, New York (November 2, 2012, 5:08 PM EDT) -- The European Commission has approved Dutch biotech company uniQure’s fat processing disorder treatment Glybera, making it the first gene therapy medicine approved for use in the Western world, the company announced Friday.

Glybera has been approved for use by sufferers of the rare genetic disorder lipoprotein lipase deficiency with recurrent acute pancreatitis attacks. The therapy was given EC approval following a July recommendation by the European Medicines Agency, the European Union agency responsible for the scientific evaluation of medicines.

The treatment becomes the first gene therapy...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.